COMPASS Pathways (NASDAQ:CMPS) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report released on Friday, Benzinga reports.

A number of other equities research analysts have also recently weighed in on CMPS. Morgan Stanley started coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an overweight rating and a $30.00 price objective for the company. HC Wainwright reissued a buy rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Monday, May 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus target price of $47.40.

COMPASS Pathways Trading Down 1.3 %

NASDAQ:CMPS opened at $6.24 on Friday. The firm has a 50-day simple moving average of $7.70 and a 200-day simple moving average of $8.86. COMPASS Pathways has a one year low of $5.01 and a one year high of $12.75. The firm has a market cap of $426.69 million, a P/E ratio of -2.63 and a beta of 2.32. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). Equities analysts anticipate that COMPASS Pathways will post -2.24 EPS for the current fiscal year.

Insider Buying and Selling at COMPASS Pathways

In related news, major shareholder George Jay Goldsmith sold 25,750 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $8.96, for a total value of $230,720.00. Following the completion of the transaction, the insider now directly owns 4,010,404 shares of the company’s stock, valued at approximately $35,933,219.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 85,002 shares of company stock worth $736,921. 4.25% of the stock is owned by insiders.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in COMPASS Pathways during the 4th quarter valued at about $33,000. Conservest Capital Advisors Inc. purchased a new stake in COMPASS Pathways in the fourth quarter valued at approximately $91,000. TAP Consulting LLC increased its holdings in COMPASS Pathways by 14.7% in the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after buying an additional 1,645 shares during the period. EWA LLC purchased a new position in COMPASS Pathways during the 4th quarter worth approximately $107,000. Finally, Kennedy Capital Management LLC acquired a new stake in COMPASS Pathways during the 1st quarter valued at approximately $139,000. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.